408 related articles for article (PubMed ID: 1699653)
21. A randomized British National Lymphoma Investigation trial of CHOP vs. a weekly multi-agent regimen (PACEBOM) in patients with histologically aggressive non-Hodgkin's lymphoma.
Linch DC; Smith P; Hancock BW; Hoskin PJ; Cunningham DC; Newland AC; Milligan D; Stevenson PA; Wood JK; Maclennan KA; Vaughan B; Vaughan G; Gregory WM
Ann Oncol; 2000; 11 Suppl 1():87-90. PubMed ID: 10707786
[TBL] [Abstract][Full Text] [Related]
22. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI
J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144
[TBL] [Abstract][Full Text] [Related]
23. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial.
Martelli M; Gherlinzoni F; De Renzo A; Zinzani PL; De Vivo A; Cantonetti M; Falini B; Storti S; Meloni G; Rizzo M; Molinari AL; Lauria F; Moretti L; Lauta VM; Mazza P; Guardigni L; Pescarmona E; Pileri SA; Mandelli F; Tura S
J Clin Oncol; 2003 Apr; 21(7):1255-62. PubMed ID: 12663712
[TBL] [Abstract][Full Text] [Related]
24. Treatment of diffuse non-Hodgkin's lymphoma with combined chemotherapy using methotrexate, adriamycin, cyclophosphamide, vincristine, prednisolone and bleomycin (MACOP-B).
Sawada U; Yamazaki T; Suzuki K; Ashiya M; Satou Y; Hirano H; Tsuboi I; Sakuma A; Kura Y; Kouda K
Int J Hematol; 1992 Aug; 56(1):59-66. PubMed ID: 1382663
[TBL] [Abstract][Full Text] [Related]
25. Treatment of poor prognosis non-Hodgkin's lymphoma with intensive, inpatient combination chemotherapy of brief duration: long-term followup.
Waits TM; Greco FA; Greer JP; Hainsworth JD
Leuk Lymphoma; 1993 Aug; 10(6):453-9. PubMed ID: 7691308
[TBL] [Abstract][Full Text] [Related]
26. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.
Miller TP; Dahlberg S; Weick JK; Files JC; Eyre HJ; Pendergrass KB; Fisher RI
J Clin Oncol; 1990 Dec; 8(12):1951-8. PubMed ID: 1700079
[TBL] [Abstract][Full Text] [Related]
27. Effects of Mega-COMLA (cyclophosphamide, cytarabine, vincristine, and methotrexate followed by leucovorin and prednisone) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) in the treatment of lymphoid neoplasms with very poor prognosis.
Hainsworth JD; Wolff SN; Stein RS; Greer JP; Cousar JB; Greco FA
Cancer Treat Rep; 1986 Aug; 70(8):953-8. PubMed ID: 3015406
[TBL] [Abstract][Full Text] [Related]
28. Results of treatment with high intensity, brief duration chemotherapy in poor prognosis non-Hodgkin's lymphoma.
McMaster ML; Greer JP; Wolff SN; Johnson DH; Greco FA; Stein RS; Cousar JB; Flexner JM; Hainsworth JD
Cancer; 1991 Jul; 68(2):233-41. PubMed ID: 1712662
[TBL] [Abstract][Full Text] [Related]
29. Treatment results with an aggressive chemotherapeutic regimen (MACOP-B) for intermediate- and some high-grade non-Hodgkin's lymphomas.
Schneider AM; Straus DJ; Schluger AE; Lowenthal DA; Koziner B; Lee BJ; Wong G; Clarkson BD
J Clin Oncol; 1990 Jan; 8(1):94-102. PubMed ID: 1688617
[TBL] [Abstract][Full Text] [Related]
30. Persistent improved results after adding vincristine and bleomycin to a cyclophosphamide/hydroxorubicin/Vm-26/prednisone combination (CHVmP) in stage III-IV intermediate- and high-grade non-Hodgkin's lymphoma. The EORTC Lymphoma Cooperative Group.
Meerwaldt JH; Carde P; Somers R; Thomas J; Kluin-Nelemans JC; Bron D; Noordijk EM; Cosset JM; Bijnens L; Teodorovic I; Hagenbeek A
Ann Oncol; 1997; 8 Suppl 1():67-70. PubMed ID: 9187434
[TBL] [Abstract][Full Text] [Related]
31. Cyclophosphamide, vincristine, adriamycin, and prednisone (CHOP) with and without intermediate dose methotrexate for the treatment of non-Hodgkin's lymphomas of diffuse histology.
Gomez GA; Barcos M; Han T; Henderson ES
Cancer; 1987 Jul; 60(1):18-24. PubMed ID: 3581030
[TBL] [Abstract][Full Text] [Related]
32. Intermediate-grade lymphomas treated with cyclophosphamide-doxorubicin- vincristine-prednisone-bleomycin alternated with cyclophosphamide-methotrexate-etoposide-dexamethasone. Application of prognostic models to data analysis.
Velasquez WS; McLaughlin P; Fuller LM; Allen PK; Tucker SL; Swan F; Rodriguez MA; Hagemeister FB; Cabanillas FF
Cancer; 1994 May; 73(9):2408-16. PubMed ID: 7513251
[TBL] [Abstract][Full Text] [Related]
33. A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma.
McMaster ML; Johnson DH; Greer JP; Wolff SN; Hildreth CR; Greco FA; Hainsworth JD
Cancer; 1991 Mar; 67(6):1487-92. PubMed ID: 1705861
[TBL] [Abstract][Full Text] [Related]
34. A follow-up of a randomized study comparing two chemotherapy treatments for advanced diffuse histiocytic lymphoma.
Todd M; Cadman E; Spiro P; Bertino J; Farber L; Waldron J; Fischer D
J Clin Oncol; 1984 Sep; 2(9):986-93. PubMed ID: 6206207
[TBL] [Abstract][Full Text] [Related]
35. Long-term survival advantage of MACOP-B over CHOP in intermediate-grade non-Hodgkin's lymphoma. The Australian and New Zealand Lymphoma Group.
Wolf M; Matthews JP; Stone J; Cooper IA; Robertson TI; Fox RM
Ann Oncol; 1997; 8 Suppl 1():71-5. PubMed ID: 9187435
[TBL] [Abstract][Full Text] [Related]
36. Results of a randomized phase III trial in children and adolescents with advanced stage diffuse large cell non-Hodgkin's lymphoma: a Pediatric Oncology Group study.
Laver JH; Mahmoud H; Pick TE; Hutchison RE; Weinstein HJ; Schwenn M; Weitzman S; Murphy SB; Ochoa S; Shuster JJ
Leuk Lymphoma; 2002 Jan; 43(1):105-9. PubMed ID: 11908712
[TBL] [Abstract][Full Text] [Related]
37. Reduced-dose chop therapy for elderly patients with non-Hodgkin's lymphoma.
Mori M; Niitsu N; Takagi T; Tomiyama J; Matsue T; Nakagawa Y; Okamoto R
Leuk Lymphoma; 2001 Apr; 41(3-4):359-66. PubMed ID: 11378549
[TBL] [Abstract][Full Text] [Related]
38. Combination chemotherapy for advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies.
Anderson KC; Skarin AT; Rosenthal DS; MacIntyre JM; Pinkus GS; Case DC; Leonard RC; Canellos GP
Cancer Treat Rep; 1984 Nov; 68(11):1343-50. PubMed ID: 6209007
[TBL] [Abstract][Full Text] [Related]
39. Phase III trial of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) versus cisplatin, etoposide, bleomycin and prednisone (CisEBP) for the treatment of advanced non-Hodgkin's lymphoma of high grade malignancy. The Danish Lymphoma Study Group.
Andersen J; Thorling K; Bentzen SM; Brincker H; Christensen BE; Pedersen M
Acta Oncol; 1990; 29(8):995-9. PubMed ID: 1703769
[TBL] [Abstract][Full Text] [Related]
40. CHOP with high dose cyclophosphamide consolidation versus CHOP alone as initial therapy for advanced stage, indolent non-Hodgkin's lymphomas.
Pan D; Qin J; Farber C; O'Brien J; Filippa D; Portlock CS
Leuk Lymphoma; 2003 Jun; 44(6):967-71. PubMed ID: 12854895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
